Market Overview:
The global peptides and heparin market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, such as diabetes, cancer, and osteoporosis. In addition, the increasing demand for peptide-based drugs is also contributing to the growth of this market. The insulin segment is expected to dominate the global peptides and heparin market during the forecast period from 2018 to 2030. This segment accounted for a share of more than 60% in 2017 and is projected to grow at a CAGR of 7% during the forecast period. The rising incidence of diabetes across all regions is driving the growth of this segment. In terms of application, diabetes held majority share in 2017 and it will continue its dominance by 2030 owing continuous incrementally incidences diabetic patients around world . However infectious disease (HIV/AIDS) , cancer ,and osteoporosis are other major application which are growing with highest CAGR over next decade on account their high unmet needs .
Product Definition:
Peptides are chains of amino acids, and heparin is a naturally occurring anticoagulant found in mammalian tissues.
Insulin:
Insulin is a peptide hormone. It's main functions are to enable the entry of glucose into the blood cells and to store energy in the form of glycogen in liver, muscle and fat tissues. Insulin opens a channel between cell membranes allowing sugar to enter into cells.
Teriparatide:
Teriparatide is a peptide heparin, which is used in the treatment of hypertension and to prevent strokes and heart attacks. It works by increasing the strength of blood vessels by inhibiting platelet aggregation. Teriparatide was approved for sale in Japan in March 2000, Europe in June 2000, U.S.
Application Insights:
The infectious diseases segment dominated the global peptides and heparin market in terms of revenue share in 2017. The growing prevalence of infectious diseases, such as tuberculosis, HIV, hepatitis A & B and others is anticipated to be a high rendering driver for this application. Furthermore, increasing research & development activities by various companies coupled with government initiatives are further expected to drive the market over the forecast period.
The diabetes segment is anticipated to witness lucrative growth during the forecast period owing to an increase in incidence rates coupled with rising awareness about lifestyle modifications that can prevent type 2 diabetes. Lifestyle changes include diet modification for patients affected by type 2 diabetes along with appropriate exercise program designed especially for these patients (pilates). This has led several manufacturers towards developing products specifically designed for people suffering from diabetes which will positively impact industry growth during future years.
Regional Analysis:
North America dominated the global market in 2017 owing to a rise in peptide-based drug development and approval by the U.S. FDA for various diseases, such as cancer, osteoporosis, diabetes & obesity, and infectious diseases. Moreover, increasing R&D investments by companies coupled with growing awareness about peptides among patients is expected to drive growth over the forecast period.
Asia Pacific is expected to witness lucrative growth over the forecast period due to rising geriatric population base that requires continuous treatment for various chronic conditions resulting from aging process leading to an increase in demand for calcitonin gene-related peptide (CGRP) products such as huperzine A and baclofen used for treating Alzheimer’s disease symptoms along with other CVDs including hypertension and anxiety disorders are anticipated boost product demand further fueling regional growth during the forecast period (2018 - 2030).
Growth Factors:
- Increasing demand for peptides and heparin in the pharmaceutical and biotechnology industries for the development of novel drugs and therapies.
- Growing research on peptides and heparin for their potential use in treating various diseases such as cancer, diabetes, heart disease, etc.
- Rising awareness about the benefits of peptides and heparin among consumers is driving their demand in the market.
- Technological advancements in peptide synthesis and extraction processes are aiding in increasing production capacities of manufacturers which is resulting into falling prices of these products making them more affordable to consumers.
Scope Of The Report
Report Attributes
Report Details
Report Title
Peptides and Heparin Market Research Report
By Type
Insulin, Teriparatide, Liraglutide, Leuprolide, Leuprolide, Exenatide, Calcitonin, Enaxaparin Sodium, Heparin Sodium
By Application
Diabetes, Infectious Diseases, Cancer, Osteoporosis
By Companies
Cipla Ltd., Emcure Pharmaceuticals Pvt. Ltd., Gland Pharma Limited, Troikaa Pharmaceuticals Ltd., Biological E Limited, Bharat Biotech, Samarth Life Sciences Pvt. Ltd., VHB Life Sciences Limited, Celon Laboratories Pvt. Ltd., United Biotech(P) Limited, Biocon Limited, Sun Pharmaceutical Industries Ltd., Wockhardt Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global Peptides and Heparin Market Report Segments:
The global Peptides and Heparin market is segmented on the basis of:
Types
Insulin, Teriparatide, Liraglutide, Leuprolide, Leuprolide, Exenatide, Calcitonin, Enaxaparin Sodium, Heparin Sodium
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Diabetes, Infectious Diseases, Cancer, Osteoporosis
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Cipla Ltd.
- Emcure Pharmaceuticals Pvt. Ltd.
- Gland Pharma Limited
- Troikaa Pharmaceuticals Ltd.
- Biological E Limited
- Bharat Biotech
- Samarth Life Sciences Pvt. Ltd.
- VHB Life Sciences Limited
- Celon Laboratories Pvt. Ltd.
- United Biotech(P) Limited
- Biocon Limited
- Sun Pharmaceutical Industries Ltd.
- Wockhardt Ltd.
Highlights of The Peptides and Heparin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Insulin
- Teriparatide
- Liraglutide
- Leuprolide
- Leuprolide
- Exenatide
- Calcitonin
- Enaxaparin Sodium
- Heparin Sodium
- By Application:
- Diabetes
- Infectious Diseases
- Cancer
- Osteoporosis
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Peptides and Heparin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Peptides are short chains of amino acids. Heparin is a blood thinner that helps prevent clots from forming in the blood.
Some of the major companies in the peptides and heparin market are Cipla Ltd., Emcure Pharmaceuticals Pvt. Ltd., Gland Pharma Limited, Troikaa Pharmaceuticals Ltd., Biological E Limited, Bharat Biotech, Samarth Life Sciences Pvt. Ltd., VHB Life Sciences Limited, Celon Laboratories Pvt. Ltd., United Biotech(P) Limited, Biocon Limited, Sun Pharmaceutical Industries Ltd., Wockhardt Ltd..
The peptides and heparin market is expected to register a CAGR of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Peptides and Heparin Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Peptides and Heparin Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Peptides and Heparin Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Peptides and Heparin Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Peptides and Heparin Market Size & Forecast, 2018-2028
4.5.1 Peptides and Heparin Market Size and Y-o-Y Growth
4.5.2 Peptides and Heparin Market Absolute $ Opportunity
Chapter 5 Global Peptides and Heparin Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Peptides and Heparin Market Size Forecast by Type
5.2.1 Insulin
5.2.2 Teriparatide
5.2.3 Liraglutide
5.2.4 Leuprolide
5.2.5 Leuprolide
5.2.6 Exenatide
5.2.7 Calcitonin
5.2.8 Enaxaparin Sodium
5.2.9 Heparin Sodium
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Peptides and Heparin Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Peptides and Heparin Market Size Forecast by Applications
6.2.1 Diabetes
6.2.2 Infectious Diseases
6.2.3 Cancer
6.2.4 Osteoporosis
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Peptides and Heparin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Peptides and Heparin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Peptides and Heparin Analysis and Forecast
9.1 Introduction
9.2 North America Peptides and Heparin Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Peptides and Heparin Market Size Forecast by Type
9.6.1 Insulin
9.6.2 Teriparatide
9.6.3 Liraglutide
9.6.4 Leuprolide
9.6.5 Leuprolide
9.6.6 Exenatide
9.6.7 Calcitonin
9.6.8 Enaxaparin Sodium
9.6.9 Heparin Sodium
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Peptides and Heparin Market Size Forecast by Applications
9.10.1 Diabetes
9.10.2 Infectious Diseases
9.10.3 Cancer
9.10.4 Osteoporosis
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Peptides and Heparin Analysis and Forecast
10.1 Introduction
10.2 Europe Peptides and Heparin Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Peptides and Heparin Market Size Forecast by Type
10.6.1 Insulin
10.6.2 Teriparatide
10.6.3 Liraglutide
10.6.4 Leuprolide
10.6.5 Leuprolide
10.6.6 Exenatide
10.6.7 Calcitonin
10.6.8 Enaxaparin Sodium
10.6.9 Heparin Sodium
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Peptides and Heparin Market Size Forecast by Applications
10.10.1 Diabetes
10.10.2 Infectious Diseases
10.10.3 Cancer
10.10.4 Osteoporosis
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Peptides and Heparin Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Peptides and Heparin Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Peptides and Heparin Market Size Forecast by Type
11.6.1 Insulin
11.6.2 Teriparatide
11.6.3 Liraglutide
11.6.4 Leuprolide
11.6.5 Leuprolide
11.6.6 Exenatide
11.6.7 Calcitonin
11.6.8 Enaxaparin Sodium
11.6.9 Heparin Sodium
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Peptides and Heparin Market Size Forecast by Applications
11.10.1 Diabetes
11.10.2 Infectious Diseases
11.10.3 Cancer
11.10.4 Osteoporosis
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Peptides and Heparin Analysis and Forecast
12.1 Introduction
12.2 Latin America Peptides and Heparin Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Peptides and Heparin Market Size Forecast by Type
12.6.1 Insulin
12.6.2 Teriparatide
12.6.3 Liraglutide
12.6.4 Leuprolide
12.6.5 Leuprolide
12.6.6 Exenatide
12.6.7 Calcitonin
12.6.8 Enaxaparin Sodium
12.6.9 Heparin Sodium
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Peptides and Heparin Market Size Forecast by Applications
12.10.1 Diabetes
12.10.2 Infectious Diseases
12.10.3 Cancer
12.10.4 Osteoporosis
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Peptides and Heparin Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Peptides and Heparin Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Peptides and Heparin Market Size Forecast by Type
13.6.1 Insulin
13.6.2 Teriparatide
13.6.3 Liraglutide
13.6.4 Leuprolide
13.6.5 Leuprolide
13.6.6 Exenatide
13.6.7 Calcitonin
13.6.8 Enaxaparin Sodium
13.6.9 Heparin Sodium
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Peptides and Heparin Market Size Forecast by Applications
13.10.1 Diabetes
13.10.2 Infectious Diseases
13.10.3 Cancer
13.10.4 Osteoporosis
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Peptides and Heparin Market: Competitive Dashboard
14.2 Global Peptides and Heparin Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Cipla Ltd.
14.3.2 Emcure Pharmaceuticals Pvt. Ltd.
14.3.3 Gland Pharma Limited
14.3.4 Troikaa Pharmaceuticals Ltd.
14.3.5 Biological E Limited
14.3.6 Bharat Biotech
14.3.7 Samarth Life Sciences Pvt. Ltd.
14.3.8 VHB Life Sciences Limited
14.3.9 Celon Laboratories Pvt. Ltd.
14.3.10 United Biotech(P) Limited
14.3.11 Biocon Limited
14.3.12 Sun Pharmaceutical Industries Ltd.
14.3.13 Wockhardt Ltd.
